ArticleRenal failure2025
Non-linear associations between serum manganese with chronic kidney disease: results from two nationwide studies in the United States and China.
Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study aimed to better evaluate the association between serum manganese (Mn) and chronic kidney disease (CKD) by using data from the United States National Health and Nutrition Examination Survey (NHANES) and the Chinese Longitudinal Healthy Longevity Study (CLHLS). MATERIALS AND
methodsA total of 15411 and 451 participants were selected from NHANES and CLHLS, respectively. The primary diagnosis of CKD was defined as eGFR <60 mL/min/1.73 m
resultsThe prevalence of CKD was estimated to be 8.1% in NHANES and 47.7% in CLHLS. After adjusting for covariates, participants with the highest quartile (Q4) of Mn had an increased likelihood of CKD than those with Q1 (OR = 0.69, 95% CI 0.56-0.84 in NHANES, and OR = 0.32, 95% CI 0.17-0.59 in CLHLS). The non-linear associations revealed that the OR values of CKD were decreased with Mn before reaching the threshold (OR = 0.65 per 1 μg/L increase of Mn in NHANES and 0.98 in CLHLS). Beyond the threshold, further increases in Mn levels were no longer associated with a statistically significant protective effect against CKD risk. This association remained robust by using the continuity of eGFR and ACR as the outcome. Exploration analysis showed that superoxide dismutase (SOD) mediated 6.7% of the effect of Mn levels on CKD.
conclusionsThe higher Mn concentration was significantly associated with a lower prevalence of CKD through different non-linear patterns.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.